Dimensional Fund Advisors LP Buys 24,673 Shares of Haleon plc (NYSE:HLN)

Dimensional Fund Advisors LP grew its stake in Haleon plc (NYSE:HLN) by 2.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,007,458 shares of the company’s stock after acquiring an additional 24,673 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Haleon were worth $8,322,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Janney Montgomery Scott LLC grew its position in shares of Haleon by 182.3% in the 1st quarter. Janney Montgomery Scott LLC now owns 438,833 shares of the company’s stock valued at $3,726,000 after purchasing an additional 283,410 shares during the period. Capstone Investment Advisors LLC acquired a new position in shares of Haleon in the 1st quarter valued at approximately $1,969,000. Wellington Management Group LLP grew its position in shares of Haleon by 164.6% in the 4th quarter. Wellington Management Group LLP now owns 13,542,346 shares of the company’s stock valued at $111,454,000 after purchasing an additional 8,423,475 shares during the period. Douglas Lane & Associates LLC grew its position in shares of Haleon by 2.1% in the 1st quarter. Douglas Lane & Associates LLC now owns 8,401,876 shares of the company’s stock valued at $71,332,000 after purchasing an additional 175,082 shares during the period. Finally, Procyon Advisors LLC grew its position in shares of Haleon by 559.9% in the 1st quarter. Procyon Advisors LLC now owns 131,665 shares of the company’s stock valued at $1,118,000 after purchasing an additional 111,713 shares during the period. 6.67% of the stock is owned by institutional investors.

Haleon Trading Down 3.2 %

NYSE:HLN opened at $10.04 on Tuesday. Haleon plc has a twelve month low of $7.70 and a twelve month high of $10.80. The company has a market cap of $45.84 billion, a P/E ratio of 33.47, a price-to-earnings-growth ratio of 3.12 and a beta of 0.26. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. The business has a 50 day moving average price of $10.11 and a two-hundred day moving average price of $9.04.

Haleon (NYSE:HLN) last posted its quarterly earnings results on Thursday, August 1st. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). Haleon had a net margin of 9.71% and a return on equity of 13.15%. The business had revenue of $3.50 billion during the quarter, compared to the consensus estimate of $3.55 billion. During the same quarter last year, the company posted $0.08 EPS. As a group, analysts expect that Haleon plc will post 0.47 EPS for the current fiscal year.

Haleon Cuts Dividend

The company also recently disclosed a semi-annual dividend, which was paid on Thursday, September 19th. Shareholders of record on Friday, August 16th were given a dividend of $0.0514 per share. This represents a yield of 1.6%. The ex-dividend date was Friday, August 16th. Haleon’s payout ratio is 33.33%.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on HLN. Berenberg Bank began coverage on Haleon in a research report on Tuesday, August 6th. They issued a “buy” rating for the company. UBS Group raised Haleon to a “strong-buy” rating in a research report on Tuesday, October 1st. Morgan Stanley upped their price target on Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a research report on Friday, September 20th. Finally, The Goldman Sachs Group downgraded Haleon from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 6th. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $10.95.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.